Future subcutaneous Herceptin studies could lead to patient-administration
This article was originally published in Scrip
Executive Summary
Phase III data from the HannaH trial of a subcutaneous formulation of Herceptin (trastuzumab) compared with the standard intravenous infusion in women with HER2-positive early breast cancer demonstrated comparable efficacy, said Roche.